Posted: 23 October 2025
Noxopharm Limited (ASX:NOX) announced that it had been granted its first United States patent for the company’s Sofra™ technology platform, marking a key milestone in its expanding oncology research portfolio.
The patent, issued by the United States Patent and Trademark Office, covers Noxopharm’s immune-modulatory oligonucleotides designed to harness the body’s own immune system to fight cancer. Classified as a ‘first-tier’ composition of matter patent, it protects the structural makeup of Noxopharm’s assets and strengthens the company’s development pipeline for novel therapeutic compounds.
“This first US patent represents a major milestone for the Sofra platform,” said Noxopharm CEO Dr Gisela Mautner. “The development of medicines that use the body’s own defences to battle cancer has led to significant breakthroughs in recent years. The global immuno-oncology market is already sizeable at around US$36 billion and is expected to grow by 16% annually to reach approximately US$88 billion by 2030.”
Filed in collaboration with the Hudson Institute of Medical Research, the patent forms part of a broader suite of applications aimed at safeguarding Noxopharm’s cancer-related intellectual property. The Sofra platform, originally designed to mitigate inflammation in autoimmune and chronic diseases, has now demonstrated potential to stimulate immune responses against uncontrolled cancer growth.
The company confirmed that ongoing efforts are centred on advancing SOF-SKN™, a first-in-class drug candidate currently in clinical trials, alongside continued exploration of the Sofra platform’s cancer and inflammation applications.
The granting of this patent was viewed as future-proofing Noxopharm’s pipeline in the rapidly expanding immuno-oncology sector.
Find out more here.
